Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:41 UTC |
---|
HMDB ID | HMDB0014623 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Lenalidomide |
---|
Description | Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia ] |
---|
Structure | NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) |
---|
Synonyms | Value | Source |
---|
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline | ChEBI | 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione | ChEBI | Revlimid | ChEBI | CC-5013 | HMDB | CDC 501 | HMDB | IMiD3 | HMDB | Revimid | MeSH, HMDB | Celgene brand OF lenalidomide | MeSH, HMDB | IMiD3 CPD | MeSH, HMDB |
|
---|
Chemical Formula | C13H13N3O3 |
---|
Average Molecular Weight | 259.2606 |
---|
Monoisotopic Molecular Weight | 259.095691297 |
---|
IUPAC Name | 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione |
---|
Traditional Name | lenalidomide |
---|
CAS Registry Number | 191732-72-6 |
---|
SMILES | NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O |
---|
InChI Identifier | InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) |
---|
InChI Key | GOTYRUGSSMKFNF-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Isoindoles and derivatives |
---|
Sub Class | Isoindolines |
---|
Direct Parent | Isoindolones |
---|
Alternative Parents | |
---|
Substituents | - Isoindolone
- Alpha-amino acid or derivatives
- Isoindole
- Piperidinedione
- Piperidinone
- Delta-lactam
- Benzenoid
- Piperidine
- Tertiary carboxylic acid amide
- Carboxylic acid imide, n-unsubstituted
- Dicarboximide
- Carboxylic acid imide
- Lactam
- Carboxamide group
- Amino acid or derivatives
- Azacycle
- Carboxylic acid derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Primary amine
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 2.33 g/L | Not Available | LogP | -0.4 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Lenalidomide,1TMS,isomer #1 | C[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O | 2796.3 | Semi standard non polar | 33892256 | Lenalidomide,1TMS,isomer #1 | C[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O | 2726.2 | Standard non polar | 33892256 | Lenalidomide,1TMS,isomer #1 | C[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O | 4146.3 | Standard polar | 33892256 | Lenalidomide,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)CCC(N2CC3=C(N)C=CC=C3C2=O)C1=O | 2618.4 | Semi standard non polar | 33892256 | Lenalidomide,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)CCC(N2CC3=C(N)C=CC=C3C2=O)C1=O | 2639.2 | Standard non polar | 33892256 | Lenalidomide,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)CCC(N2CC3=C(N)C=CC=C3C2=O)C1=O | 4008.2 | Standard polar | 33892256 | Lenalidomide,2TMS,isomer #1 | C[Si](C)(C)N(C1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)[Si](C)(C)C | 2721.8 | Semi standard non polar | 33892256 | Lenalidomide,2TMS,isomer #1 | C[Si](C)(C)N(C1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)[Si](C)(C)C | 2793.7 | Standard non polar | 33892256 | Lenalidomide,2TMS,isomer #1 | C[Si](C)(C)N(C1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)[Si](C)(C)C | 3902.1 | Standard polar | 33892256 | Lenalidomide,2TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)N([Si](C)(C)C)C1=O)C2=O | 2686.8 | Semi standard non polar | 33892256 | Lenalidomide,2TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)N([Si](C)(C)C)C1=O)C2=O | 2741.1 | Standard non polar | 33892256 | Lenalidomide,2TMS,isomer #2 | C[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)N([Si](C)(C)C)C1=O)C2=O | 3583.7 | Standard polar | 33892256 | Lenalidomide,3TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC(N2CC3=C(C=CC=C3N([Si](C)(C)C)[Si](C)(C)C)C2=O)C1=O | 2571.5 | Semi standard non polar | 33892256 | Lenalidomide,3TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC(N2CC3=C(C=CC=C3N([Si](C)(C)C)[Si](C)(C)C)C2=O)C1=O | 2837.6 | Standard non polar | 33892256 | Lenalidomide,3TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC(N2CC3=C(C=CC=C3N([Si](C)(C)C)[Si](C)(C)C)C2=O)C1=O | 3315.5 | Standard polar | 33892256 | Lenalidomide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O | 3050.7 | Semi standard non polar | 33892256 | Lenalidomide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O | 2961.8 | Standard non polar | 33892256 | Lenalidomide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O | 4137.0 | Standard polar | 33892256 | Lenalidomide,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)CCC(N2CC3=C(N)C=CC=C3C2=O)C1=O | 2869.2 | Semi standard non polar | 33892256 | Lenalidomide,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)CCC(N2CC3=C(N)C=CC=C3C2=O)C1=O | 2871.9 | Standard non polar | 33892256 | Lenalidomide,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)CCC(N2CC3=C(N)C=CC=C3C2=O)C1=O | 4002.8 | Standard polar | 33892256 | Lenalidomide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)[Si](C)(C)C(C)(C)C | 3181.7 | Semi standard non polar | 33892256 | Lenalidomide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)[Si](C)(C)C(C)(C)C | 3247.6 | Standard non polar | 33892256 | Lenalidomide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O)[Si](C)(C)C(C)(C)C | 3874.6 | Standard polar | 33892256 | Lenalidomide,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)N([Si](C)(C)C(C)(C)C)C1=O)C2=O | 3131.6 | Semi standard non polar | 33892256 | Lenalidomide,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)N([Si](C)(C)C(C)(C)C)C1=O)C2=O | 3194.0 | Standard non polar | 33892256 | Lenalidomide,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=CC=CC2=C1CN(C1CCC(=O)N([Si](C)(C)C(C)(C)C)C1=O)C2=O | 3589.3 | Standard polar | 33892256 | Lenalidomide,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC(N2CC3=C(C=CC=C3N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C2=O)C1=O | 3262.2 | Semi standard non polar | 33892256 | Lenalidomide,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC(N2CC3=C(C=CC=C3N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C2=O)C1=O | 3481.9 | Standard non polar | 33892256 | Lenalidomide,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC(N2CC3=C(C=CC=C3N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C2=O)C1=O | 3449.2 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Lenalidomide GC-MS (Non-derivatized) - 70eV, Positive | splash10-01si-4950000000-d56c036a1d29e5a9442f | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenalidomide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Lenalidomide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Lenalidomide LC-ESI-qTof , Positive-QTOF | splash10-0002-1920000000-c10c48acd9b8123e3505 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lenalidomide , positive-QTOF | splash10-0002-1920000000-c10c48acd9b8123e3505 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 10V, Positive-QTOF | splash10-03dl-0090000000-2431a4e4063fb866e502 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 20V, Positive-QTOF | splash10-03dl-0590000000-3bd8341d78d9f0bb2185 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 40V, Positive-QTOF | splash10-0006-5900000000-ede52ce7143fcbe39e3c | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 10V, Negative-QTOF | splash10-0a4i-0190000000-a51e8a05d578a97d3916 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 20V, Negative-QTOF | splash10-0btc-2980000000-9fa6887f8d1dd5044b78 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 40V, Negative-QTOF | splash10-000f-9500000000-60ff64f6a1048a417538 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 10V, Positive-QTOF | splash10-03dj-0590000000-f93c028e30eeeb33fb07 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 20V, Positive-QTOF | splash10-01pk-0970000000-62ad8f815b005ef334f6 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 40V, Positive-QTOF | splash10-001j-2900000000-882d6b2043b051c57a33 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 10V, Negative-QTOF | splash10-0a4i-0090000000-7a47503a13a4776dc84e | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 20V, Negative-QTOF | splash10-0a4u-1690000000-9c997f4a738ff527b14a | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lenalidomide 40V, Negative-QTOF | splash10-0006-6910000000-618785cddde3e646877b | 2021-09-25 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
|
---|
General References | - List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. [PubMed:15703420 ]
- Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. [PubMed:16344099 ]
- Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. [PubMed:16569772 ]
|
---|